These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 32734457)
1. Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457 [TBL] [Abstract][Full Text] [Related]
2. Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111 [TBL] [Abstract][Full Text] [Related]
3. Establishment and prospective validation of an SUV Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749 [No Abstract] [Full Text] [Related]
4. Detection Rate of Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295 [TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
6. Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341 [TBL] [Abstract][Full Text] [Related]
7. Clinical Factors That Influence Repeat Thin P; Hotta M; Gafita A; Grogan T; Czernin J; Calais J; Sonni I J Nucl Med; 2024 Oct; 65(10):1571-1576. PubMed ID: 39168522 [TBL] [Abstract][Full Text] [Related]
9. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644 [TBL] [Abstract][Full Text] [Related]
10. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer. Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469 [TBL] [Abstract][Full Text] [Related]
11. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492 [TBL] [Abstract][Full Text] [Related]
12. Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy. Gupta M; Choudhury PS; Rawal S; Gupta G Urol Ann; 2018; 10(2):150-153. PubMed ID: 29719325 [TBL] [Abstract][Full Text] [Related]
13. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
14. The use of Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382 [TBL] [Abstract][Full Text] [Related]
15. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389 [TBL] [Abstract][Full Text] [Related]
16. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048 [TBL] [Abstract][Full Text] [Related]